Lifecore Biomedical
Lifecore Biomedical, LLC, a wholly owned subsidiary of Landec Corporation (Nasdaq: LNDC), is dedicated to the development of technically.
Launch date
Employees
Market cap
$158m
Enterprise valuation
$280m (Public information from Sep 2024)
Share price
$5.62 LFCR
Chaska Minnesota (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 590m | 544m | 186m | 103m | 128m | 128m | 140m |
| % growth | 6 % | (8 %) | (66 %) | (44 %) | 24 % | - | 9 % |
| EBITDA | (12.6m) | 14.1m | 21.2m | (11.1m) | (1.4m) | 20.2m | 25.3m |
| % EBITDA margin | (2 %) | 3 % | 11 % | (11 %) | (1 %) | 16 % | 18 % |
| Profit | (38.2m) | (32.7m) | (97.2m) | (102m) | 12.0m | (36.4m) | (26.0m) |
| % profit margin | (6 %) | (6 %) | (52 %) | (99 %) | 9 % | (28 %) | (19 %) |
| EV / revenue | 0.5x | 0.6x | 1.5x | 2.3x | 1.3x | 1.1x | 1.0x |
| EV / EBITDA | -25.0x | 24.4x | 13.5x | -21.6x | -124.3x | 6.7x | 5.3x |
| R&D budget | 11.1m | 10.2m | 7.8m | 8.2m | 8.6m | - | - |
| R&D % of revenue | 2 % | 2 % | 4 % | 8 % | 7 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
N/A | Acquisition | ||
* | $38.8m | Post IPO Convertible | |
* | $150m | Post IPO Debt | |
* | N/A | $8.0m | Post IPO Debt |
| Total Funding | - | ||
Recent News about Lifecore Biomedical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.